OpenAI acquires startup Orchestra Bio to beef up its biotech business
OpenAI says it's adding Orchestra's team and technology to work on Rosalind, its AI model for life sciences research, and to its related Rosalind Workbench tool, a harness that aims to help researchers plan experiments and analyze results.
TL;DR
- OpenAI acquired Orchestra Bio, an AI biotech software startup.
- Orchestra Bio develops AI agents to assist biotech companies with drug discovery operations.
- The acquisition will enhance OpenAI's Rosalind AI model and Rosalind Workbench tool for life sciences research.
- This move exemplifies how large AI labs are expanding their software offerings into major industries like pharmaceuticals.
- The terms of the deal were not disclosed.